Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDYL2 | Q8N8U2 | 1/20 | 0.52 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | PPARD | Q03181 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14484996 | 0.89 | CDYL2 (0.58) | CDYL2CDYLATMTP53MAPT | |
| SCHEMBL28567244 | 0.88 | CDYL2 (0.51) | CDYL2CDYLATMTP53MAPT | |
| SCHEMBL7383444 | 0.88 | CDYL2 (0.54) | CDYL2CDYLATMTP53MAPT | |
| SCHEMBL14485127 | 0.81 | TNKS (0.46) | MAPTKMT2AMEN1GAAALDH1A1 | |
| SCHEMBL2878152 | 0.80 | EGFR (0.44) | CDYL2CDYLTP53MAPTKMT2A | |
| SCHEMBL8140009 | 0.78 | EGFR (0.43) | CDYL2CDYLMAPTKMT2AMEN1 | |
| SCHEMBL9376612 | 0.78 | PGR (0.43) | CDYL2CDYLTP53MAPTGAA | |
| SCHEMBL1129626 | 0.77 | HTR7 (0.49) | CDYL2CDYLTP53MAPTGAA | |
| SCHEMBL7382582 | 0.77 | CDYL2 (0.57) | CDYL2CDYLTP53MAPTKMT2A | |
| SCHEMBL7385586 | 0.77 | CDYL2 (0.60) | CDYL2CDYLTP53MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2023-01-12 | — | — | US | disclosed |
| US-11034668-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-10370358-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20180194746-A1 | Compounds For the Treatment of HIV | GILEAD SCIENCES, INC. | 2018-07-12 | — | — | US | disclosed |
| US-9944619-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2017-05-18 | — | — | US | disclosed |
| US-9540343-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| EP-2079467-B1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2015-11-18 | — | — | EP | disclosed |
| EP-2729448-B1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES INC (US) | 2015-09-09 | — | — | EP | disclosed |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| EP-2729448-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | Gilead Sciences, Inc. (US) | 2014-05-14 | — | — | EP | disclosed |
| WO-2013006738-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2013-01-10 | — | — | WO | disclosed |
| US-8039484-B2 | Antidiabetic bicyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2011-10-18 | — | — | US | disclosed |
| US-20100105725-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2010-04-29 | — | — | US | disclosed |
| EP-2079467-A2 | ANTIDIABETIC BICYCLIC COMPOUNDS | Merck & Co., Inc. (US) | 2009-07-22 | — | — | EP | disclosed |
| WO-2008054675-A2 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK & CO., INC. (US) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10370358-B2 | Compounds for the treatment of HIV | CCR5, NPC1, FURIN | CDYL2 4495/4885CDYL 4620/4885ATM 4697/4885 |
| US-20100105725-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | GPR119, FFAR2, GPR65 | CDYL2 778/4885CDYL 928/4885ATM 4565/4885 |
| US-20180194746-A1 | Compounds For the Treatment of HIV | CCR5, NPC1, FURIN | CDYL2 4495/4885CDYL 4620/4885ATM 4697/4885 |
| US-11034668-B2 | Compounds for the treatment of HIV | CCR5, NPC1, FURIN | CDYL2 4495/4885CDYL 4620/4885ATM 4697/4885 |
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | CDYL2 4495/4885CDYL 4620/4885ATM 4697/4885 |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | CDYL2 4495/4885CDYL 4620/4885ATM 4697/4885 |
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | CDYL2 4495/4885CDYL 4620/4885ATM 4697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.